A

    AVDL (AVDL)

    Official site

    DRUG MANUFACTURERS - SPECIALTY & GENERIC

    $21.64
    +0.00 (+0.00%)

    Last updated: Feb 12, 2026 at 4:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    61%(23/38)
    Avg Surprise
    +327.06%

    Upcoming Estimates

    Period ending Mar 31, 2026
    EPS Consensus$0.13
    Range$0.08 - $0.17
    5 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$0.12-9.6%
    60d ago$0.13+0.0%
    30d ago$0.13+0.0%
    7d ago$0.11-11.8%
    Current$0.13
    Revenue Consensus
    $80M
    Range$75M - $87M
    6 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Mar 26EST
    		-$0.13---
    Dec 25
    Reported Mar 9
    		$0.00N/A-100.00%Miss+100.0%
    Sep 25
    Reported Nov 4
    		$0.00N/A-99.71%Miss+100.7%
    Jun 25
    Reported Aug 7
    		$0.10$0.02+400.00%Beat+171.4%
    Mar 25
    Reported May 7
    		$-0.05$-0.07+28.57%Beat+83.3%
    Dec 24
    Reported Mar 3
    		$-0.05$-0.05+0.00%Beat+84.4%
    Sep 24
    Reported Nov 12
    		$-0.03$-0.06+50.00%Beat+92.7%
    Jun 24
    Reported Aug 8
    		$-0.14$-0.17+17.65%Beat+80.0%
    Mar 24
    Reported May 8
    		$-0.30$-0.25-20.00%Miss+37.5%
    Dec 23
    Reported Mar 4
    		$-0.32$-0.28-14.29%Miss+27.3%
    Sep 23
    Reported Nov 8
    		$-0.41$-0.35-17.14%Miss-24.2%
    Jun 23
    Reported Aug 9
    		$-0.70$-0.39-79.49%Miss-40.0%
    Mar 23
    Reported May 4
    		$-0.48$-0.37-29.73%Miss-6.7%
    Dec 22
    Reported Mar 30
    		$-0.44$-0.30-46.67%Miss-15.8%
    Sep 22
    Reported Nov 9
    		$-0.33$-0.22-50.00%Miss+13.2%
    Jun 22
    Reported Aug 9
    		$-0.50$-0.41-21.95%Miss-51.5%
    Mar 22
    Reported May 9
    		$-0.45$-0.44-2.27%Miss-95.7%
    Dec 21
    Reported Mar 17
    		$-0.38$-0.42+9.52%Beat-58.3%
    Sep 21
    Reported Nov 8
    		$-0.38$-0.38+0.00%Beat-90.0%
    Jun 21
    Reported Aug 9
    		$-0.33$-0.31-6.45%Miss-106.3%
    Mar 21
    Reported May 10
    		$-0.23$-0.32+28.13%Beat-1050.0%
    Dec 20
    Reported Mar 9
    		$-0.24$-0.28+14.29%Beat-242.9%
    Sep 20
    Reported Nov 9
    		$-0.20$-0.26+23.08%Beat+16.7%
    Jun 20
    Reported Aug 10
    		$-0.16$-0.18+11.11%Beat+30.4%
    Mar 20
    Reported May 11
    		$-0.02N/A+92.59%Beat+94.3%
    Dec 19
    Reported Mar 12
    		$-0.07N/A+72.00%Beat+95.9%
    Sep 19
    Reported Nov 12
    		$-0.24$-0.27+11.11%Beat+44.2%
    Jun 19
    Reported Aug 9
    		$-0.23$-0.29+20.69%Beat-155.6%
    Mar 19
    Reported May 8
    		$-0.35$-0.49+28.57%Beat-9.4%
    Dec 18
    Reported Mar 15
    		$-1.72$-2.34+26.50%Beat-421.2%
    Sep 18
    Reported Nov 5
    		$-0.43$-0.40-7.50%Miss-182.7%
    Jun 18
    Reported Aug 7
    		$-0.09N/A+70.00%Beat-113.2%
    Mar 18
    Reported May 2
    		$-0.32$-0.39+17.95%Beat-150.0%
    Dec 17
    Reported Mar 8
    		$-0.33$-0.25-32.00%Miss-400.0%
    Sep 17
    Reported Nov 8
    		$0.52$0.02+2410.86%Beat+196.3%
    Jun 17
    Reported Aug 8
    		$0.68$0.04+1500.00%Beat-
    Mar 17
    Reported May 9
    		$0.64$0.01+8105.13%Beat-
    Dec 16
    Reported Mar 7
    		$0.11$-0.21+152.38%Beat-
    Sep 16
    Reported Nov 7
    		$-0.54$-0.23-134.78%Miss-

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit MarginN/AOperating MarginN/A
    ROEN/AROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current RatioN/AQuick RatioN/A
    Trading Statistics
    BetaN/AAvg VolumeN/A
    52-Week HighN/A52-Week LowN/A

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$21.61
    SMA 20$21.57
    SMA 50$21.50
    SMA 200$15.49
    EMA 10$21.61
    EMA 20$21.58
    EMA 50$21.16
    EMA 200$16.67

    MACD

    Line: 0.06Signal: 0.06Hist: -0.00

    ADX

    ADX: 46.5+DI: 27.3-DI: 6.1

    Aroon & PSAR

    Aroon Up96.0
    Aroon Down4.0
    PSAR$22.02

    Bollinger Bands

    Upper Band$21.68
    Lower Band$21.45
    %B Position107%(Upper)
    Band Width0.82

    RSI (14-Day)

    Neutral
    61.6

    Momentum Oscillators

    Stoch %K55.9
    Stoch %D62.7
    Williams %R-48.0
    ROC (10d)0.4%
    Momentum0.08
    CCI (20d)93.3
    MFI (14d)90.8

    Volatility Measures

    ATR (14d)$0.08(0.4%)
    StdDev (20d)0.06
    Hist Vol2.5%(Low)

    Volume Flow

    VWAP$21.64
    OBV102.3M
    AD Line-22.4M
    CMF (20d)-0.728

    Volume Metrics

    Avg Vol (20d)3.0M
    Vol Ratio0.0x(Low)
    VWMA (20d)$21.61

    Pivot Points

    R3$21.85
    R2$21.81
    R1$21.72
    Pivot Point$21.68
    S1$21.59
    S2$21.55
    S3$21.46

    Advanced Oscillators

    TSI21.22
    Ultimate Osc28.5
    KST5.15

    Financial Data

    QuarterSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Total Revenue$77.47M$68.13M$52.51M$50.41M$50.02M$41.50M$27.18M$19.45M$7.01M$1.50M$0$0
    Cost of Revenue$-3,001,000$6.37M$5.58M$4.81M$6.16M$2.79M$1.52M$693,000$117,000$36,000$0$586,000
    Gross Profit$80.47M$61.76M$46.93M$45.60M$43.87M$38.72M$25.66M$18.76M$6.90M$1.46M$0$-586,000
    Operating Expenses$78.53M$52.88M$49.94M$48.90M$44.20M$51.46M$51.69M$43.66M$42.01M$51.00M$28.30M$22.63M
    R&D$27.01M$4.25M$4.35M$4.27M$3.80M$4.05M$3.07M$2.36M$2.85M$4.22M$3.83M$6.24M
    SG&A$51.52M$48.62M$45.58M$44.62M$40.39M$47.41M$48.62M$41.30M$39.16M$46.78M$24.47M$16.39M
    Operating Income$1.94M$8.88M$-3,001,000$-3,297,000$-327,000$-12,741,000$-26,035,000$-24,900,000$-35,110,000$-49,541,000$-28,298,000$-23,216,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$2.42M$2.35M$2.24M$2.70M$2.82M$2.72M$2.59M$2.35M$1.98M$2.29M$3.26M$3.25M
    Income Before Tax$54,000$6.50M$-4,842,000$-4,963,000$-2,537,000$-14,331,000$-27,249,000$-28,886,000$-36,185,000$-64,342,000$-31,364,000$-27,365,000
    Income Tax Expense$34,000$-3,170,000$78,000$80,000$88,000$-509,000$93,000$-100,000$89,000$90,000$-580,000$85,000
    Net Income$20,000$9.66M$-4,920,000$-5,043,000$-2,625,000$-13,822,000$-27,342,000$-28,786,000$-36,274,000$-64,432,000$-30,784,000$-27,450,000
    EBITDA$3.58M$9.92M$-1,779,000$-1,593,000$1.32M$-11,178,000$-24,116,000$-26,532,000$-33,612,000$-61,446,000$-27,517,000$-23,524,000
    EBIT$2.47M$8.85M$-2,604,000$-2,261,000$283,000$-11,615,000$-24,657,000$-26,532,000$-34,207,000$-62,047,000$-28,105,000$-24,110,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about AVDL

    News

    Avadel Pharmaceuticals (AVDL) Goldman Sachs 45th Annual Global Healthcare Conference summary

    This article summarizes Avadel Pharmaceuticals' (AVDL) presentation at the Goldman Sachs 45th Annual Global Healthcare Conference. The company highlighted the market opportunity for its narcolepsy drug, LUMRYZ, targeting a significant patient population. LUMRYZ is positioned as a preferred once-nightly oxybate, backed by strong clinical and real-world data showing patient preference and efficacy.

    Quartr•7/16/26•
    Bullish

    Avadel Pharmaceuticals (AVDL) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

    Avadel Pharmaceuticals (AVDL) presented a summary of its performance at the H.C. Wainwright 26th Annual Global Investment Conference 2024, highlighting four consecutive quarters of exceeding estimates and nearing cash flow break-even. The company's product launch has rapidly transitioned, strengthening its balance sheet, and market research indicates potential blockbuster status, driven by strong patient acquisition and market expansion across various patient segments. The addressable market is estimated at over $1 billion with early signs of broader adoption, particularly among previously untreated patients.

    Quartr•7/16/26•
    Neutral

    If You Invested $1,000 in Avadel Pharmaceu (AVDL)

    This article examines the historical performance of a $1,000 investment in Avadel Pharmaceuticals (AVDL) over various periods, showing significant returns in the short term but underperformance compared to the S&P 500 over the last decade. It also provides a detailed overview of Avadel Pharmaceuticals, focusing on its biopharmaceutical operations, commercial product LUMRYZ for narcolepsy, broader sleep medicine pipeline, and the ongoing acquisition by Alkermes plc. The company's business model, regulatory framework, and corporate transactions are discussed to give context to its stock performance.

    Stock Titan•7/4/26•
    Somewhat-Bullish

    Avadel Pharmaceuticals PLC (AVDL) Technical Analysis: Support, Resistance, Indicators & Moving Averages

    This article provides a technical analysis of Avadel Pharmaceuticals PLC (AVDL), focusing on its support and resistance levels, various technical indicators, and moving averages. The stock's current price momentum score is 4.28, and it is trading between resistance at $21.77 and support at $21.49. Based on moving averages, the current signal for AVDL is a "Sell," with technical indicators showing a mix of buy and sell signals.

    TradingKey•6/19/26•
    Somewhat-Bearish

    Avadel Pharmaceuticals PLC

    This article provides a revenue breakdown for Avadel Pharmaceuticals PLC (AVDL) as of March 3, 2025. It details revenue contributions by business segments, including Vazculep, Akovaz, and Bloxiverz, and notes that 100% of its reported revenue comes from the United States. The company had a market cap of $2.12 billion with its stock closing at $21.326.

    TradingKey•6/18/26•
    Neutral

    Frequently Asked Questions About AVDL

    Does AVDL pay dividends?
    AVDL (AVDL) does not currently pay a regular dividend.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In